Back to Newsroom

Forbes: Biotech Entrepreneur’s Fortune Nearly Doubles After Strong Clinical Trials For Cancer Treatment

Alan Auerbach is the brains and leadership behind Puma Biotechnology PBYI +2.59%, a biopharma acquirer and developer of innovative cancer treatments that has had a great stock run this past week. The Los Angeles-based company’s shares surged 88 percent from Wednesday to Friday, closing the week at $86.75 per share.